Indian Pharmaceutical Supplier to Germany.
Germany is the most exacting prescription-medicines market in Europe, and the one where a Qualified Person signature at an EU-licensed site sits between every Indian batch and the ward trolley. M Care operates as an Indian pharmaceutical supplier to Germany through a Mumbai-led account structure, a London commercial desk for spoken-English contact hours, and German-language regulatory partners covering BfArM, PEI and G-BA work. The volume profile here is deliberately focused, oncology, rare-disease, cold-chain biologicals, and §73 AMG named-patient imports, rather than broad ambient generics, reflecting where Indian manufacturing depth and German buyer demand actually meet.
The German regulatory map, and how we work it.
The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the competent authority for human medicinal products. For biologicals, vaccines, advanced-therapy medicinal products and blood components, the Paul-Ehrlich-Institut (PEI) takes the lead. Routine commercial market entry for a prescription product runs through either a centralised EMA procedure, a Decentralised Procedure (DCP) with BfArM as Reference Member State, or a Mutual Recognition Procedure (MRP) based on an existing EU MA. Active-assessment time on a DCP is typically 210 days plus clock-stops; renewals and variations follow EMA-aligned timelines.
QP certification pharmaceutical import Germany is not negotiable. Every batch of a commercial product entering the EU must be released by a Qualified Person at an EU-licensed manufacturing or importation site before it is placed on the market. M Care contracts with QP providers in Germany and the Netherlands who take delivery of the Indian batch, review the complete Chain-of-Evidence package against the EU dossier, retain samples, and issue the QP release before stock moves into the Apotheken, Großhandel or Krankenhausapotheken channel. For single-patient supply of products not licensed in Germany, the §73 Abs. 3 AMG route allows import on the written request of a treating physician via a German pharmacy, similar in philosophy to the UK named-patient regime but with its own documentation flow.
Labelling and safety features are strictly enforced. Packs carry a German-language Beipackzettel, Fachinformation for healthcare professionals, and the Falsified Medicines Directive 2D Data Matrix uploaded to the securPharm national repository before release. As an Indian generic supplier BfArM has registered product for, we build the eCTD dossier around ICH Zone II/IVa stability data, full bioequivalence where required, and a CMC section detailed to Annex 1 expectations.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Five capabilities, EU-grade.
BfArM & PEI dossier work
eCTD dossier authoring for DCP and MRP submissions with BfArM and, for biologicals and vaccines, PEI. Bioequivalence strategy, ICH Zone II/IVa stability bridging, German-language SmPC, PIL and Fachinformation prepared by our regulatory partner in Germany.
QP release network
Qualified Person batch release through contracted EU-licensed sites in Germany and the Netherlands. Full Chain-of-Evidence review, retained-sample storage, CoA cross-verification, securPharm serial activation and release certificate issued before stock leaves the bonded warehouse.
§73 AMG named-patient
Single-patient imports under §73 Abs. 3 AMG on physician request via a German pharmacy, typically 7 to 14 days from order. Indian-side documentation, CoA, manufacturing-licence extract and QP spot-check handled as a package, so the requesting Apotheke deals with one invoice and one delivery note.
Hospital & homecare supply
German hospital pharmaceutical import from India into Krankenhausapotheken and specialist homecare providers, oncology-heavy, with validated 2–8 °C and −25 °C cold-chain into FRA. Documentation matched to Arzneimittelgesetz, §20 ApoG and local Apothekerkammer requirements.
Tender & rebate support
Supply-side input into AOK-style Rabattvertrag rebate tenders and Festbeträge reference-price-bracket generics. We hold capacity statements for 12 to 24 months of cover on a contracted line, with penalty clauses for underdelivery priced transparently into the tender response.
Mumbai to Frankfurt, and onward into the Apotheke.
The default lane for German volume is BOM to Frankfurt (FRA), direct, 8 to 9 hours in the air. Fraport is Pharma.Aero member and holds CEIV Pharma accreditation across handlers; the temperature-controlled pharma corridor from airside GDP-compliant acceptance through to bonded put-away at our QP partner's warehouse near FRA closes a typical door-to-door window at 3 to 5 days including QP release. Leipzig (LEJ) is a secondary air hub, particularly useful for repositioning stock into eastern and southern Germany overnight.
Cold-chain flies on Envirotainer RKN and RAP active containers for 2–8 °C bulk; passive systems (Pelican BioThermal, va-Q-tec) cover smaller parcels, with continuous logging on Sensitech or Berlinger loggers. Frozen biologicals at −25 °C and ultra-low −70 °C capability are available on selected lanes with 96-hour hold validation. Sea freight via Hamburg and Bremerhaven carries ambient palletised volume where landed cost drives the tender, typically 26 to 32 days door-to-door, with full-container or less-than-container load options out of Nhava Sheva.
Commercial terms on a first German engagement are typically advance TT or LC at sight against shipping documents, transitioning to open account 30 or 60 days once the QP-release track record is established. We invoice in EUR, and we do not pass FX movement on to the buyer between quote and invoice for orders shipped within 60 days of the quote date.
Where our German volume actually sits.
Germany is a focused rather than broad market for M Care. The economics of competing against German domestic manufacturing on ambient commodity generics are rarely in our favour; where we add real value is in the categories Indian manufacturing has developed genuine depth in, and where German hospital pharmacy demand is either unmet or increasingly looking outside the DACH supply base.
Oncology sits at the top of the volume mix, cytotoxic injectables, supportive care, and a growing biosimilar book into Onkologische Schwerpunktpraxen and hospital day units. Second is specialist cold-chain biologicals, including immunology and rare-disease products, where the combination of WHO-GMP + EU-GMP Indian manufacturing and a validated FRA pharma corridor is genuinely competitive. Third is §73 AMG named-patient supply, which often starts as a one-off import for an individual case and scales into a standing arrangement when the treating centre finds continuity of supply easier through us than through a re-importer.
We also maintain selective depth in anti-infectives and critical-care molecules where European supply disruption is a recurring story and where Indian manufacturing has become the de-facto global back-up. What we will not do is quote every line on a German Rabattvertrag tender sheet; focus is part of the value.
A specialist oncology centre in North Rhine-Westphalia engaged us in early 2023 for §73 AMG supply of a cytotoxic injectable facing a protracted European shortage. The Mumbai desk identified an EU-GMP-inspected partner with stock on hand, our Netherlands-based QP released the first consignment on arrival at FRA within 48 hours of wheels-down, and the centre took delivery into its Krankenhausapotheke on day 9 from initial enquiry. The arrangement has since matured into a standing §73 supply route on two oncology molecules, with an average turnaround of 11 days on replenishment orders and no temperature excursions recorded across the 2–8 °C lane over the following 14 months.
Why Indian pharma for the German market.
German procurement teams, whether in Krankenhausapotheken, at a Großhandel, or on the tender desk of a statutory health insurer, have watched the last five years of European pharma supply steadily rebalance. A significant share of finished-dose-form manufacturing now sits in India, a materially larger share of API does, and the quality floor is set by EU-GMP inspections carried out by the same BfArM and EMA officials who inspect European sites. EU-GMP supply Germany from India is already the reality in many tender lines, the only question is whether your Indian counterparty has the QP network, the German-language regulatory partner, and the willingness to absorb the responsibility of batch release before handing stock to the wholesaler.
M Care's structure is designed around that gap. You deal with one Mumbai account manager on +49-compatible English hours through the London desk, backed by a German-language regulatory partner for BfArM and PEI correspondence, plus an EU QP network on the release side. Dossiers are eCTD from day one, stability is ICH Zone II and IVa, and artwork is produced against the approved Fachinformation rather than retrofitted after a complaint. We are small enough that the person quoting a line is also the person on the call when a batch is late, and large enough, through our network of WHO-GMP and EU-GMP manufacturing partners, to carry the capacity a German hospital group or Großhandel actually needs over a 12 to 24 month tender horizon.
What German buyers usually ask us first.
Do you provide QP-released stock for the German market?
Yes. Every commercial batch entering the EU must be released by a Qualified Person at an EU-licensed site. We work with QP service providers licensed in Germany and the Netherlands who receive the Indian batch, review the full manufacturing and analytical documentation against the EU dossier, take retained samples, and issue the QP release certificate before the stock is moved into the Apotheken or Krankenhausapotheken supply chain.
Can you register a generic with BfArM from India?
Yes, through the Decentralised or Mutual Recognition Procedure with BfArM as either RMS or CMS. The typical active-review clock is 210 days plus clock-stops for queries, and we build the eCTD dossier from the Indian manufacturing partner's CTD, including bioequivalence data, stability to ICH climate zones II/IVa, and a German-language SmPC, PIL and Fachinformation. Centralised EMA filings are reserved for molecules that require them.
How does §73 AMG supply work with an Indian manufacturer?
§73 Abs. 3 of the Arzneimittelgesetz permits single-patient import of a product not licensed in Germany, on written request from the treating physician via a German pharmacy. We handle the Indian-side paperwork (CoA, batch certificate, manufacturing licence extract), the QP check on arrival, and dispatch into the requesting Apotheke, typically 7 to 14 days from order depending on molecule and cold-chain requirement.
What about securPharm serialisation and FMD compliance?
Every prescription pack destined for the German market carries a unique 2D Data Matrix (GTIN, serial, batch, expiry) and a tamper-evident seal per the Falsified Medicines Directive, uploaded to the securPharm national repository before release. We coordinate serial-number ranges with the German Marketing Authorisation Holder or our QP partner, and verify pack status is 'active' in securPharm before the stock leaves the bonded site.
Can you support AMNOG dossier work for new products?
For innovative products falling under AMNOG, the G-BA benefit-assessment dossier is typically led by the Marketing Authorisation Holder's German medical affairs team. Our role is on the manufacturing and supply side: CMC sections of the dossier, EU-GMP supply Germany from India with validated stability and capacity statements, and batch-release continuity through our QP network. For pure generics, the Festbeträge reference-price system and AOK-style rebate tenders are the relevant economic layer.
Which airports and ports do you use for German supply?
Frankfurt (FRA) is the default pharma lane from Mumbai, with the Pharma.Aero-certified, CEIV Pharma-accredited cargo handling at Fraport; direct BOM–FRA sector is 8 to 9 hours in the air and 3 to 5 days door-to-door including QP release and bonded put-away. Leipzig (LEJ) serves as a secondary air hub. Sea freight is routed via Hamburg or Bremerhaven for ambient palletised volume, typically 26 to 32 days door-to-door.
Do you handle German-language labelling and Beipackzettel?
Yes. German-language Beipackzettel (patient information leaflet), Fachinformation (SmPC for prescribers) and carton copy are mandatory for any prescription product on the German market and are produced against the approved BfArM dossier. Translation is done through our regulatory partner in Germany and reviewed by a native-speaker regulatory affairs officer before artwork is locked and sent to the Indian manufacturing partner for printing.
Why buyers choose M Care for the India → Germany corridor.
BfArM fluency
Dossiers built to the exact format BfArM reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → FRA direct air for time-critical orders, and Hamburg for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in Germany.
Top categories we ship to Germany
Anti-infectives
Penicillins, cephalosporins, carbapenems, antivirals, antimalarials — 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
Oncology
Cytotoxics, targeted therapy and supportive care — bortezomib, docetaxel, paclitaxel, gemcitabine.
Diabetes & endocrine
Insulins, oral antidiabetics, thyroid and hormonal therapy — 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals — 1,283 SKUs, our broadest catalogue.
Molecule, volume, ship-to. One working day to a quote.
Your enquiry goes directly to the account manager responsible for the Germany desk, backed by our QP and German-language regulatory partners. No call-centre hops, no generic autoresponders, just the answer a Krankenhausapotheke or Großhandel can act on.
Start a Germany enquiry → Back to all markets